Oncology Pharma (OTCMKTS:ONPH) Versus IronNet (NYSE:IRNT) Head to Head Comparison
Oncology Pharma (OTCMKTS:ONPH) Versus IronNet (NYSE:IRNT) Head to Head Comparison
IronNet (NYSE:IRNT – Get Rating) and Oncology Pharma (OTCMKTS:ONPH – Get Rating) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.
IronNet(纽约证券交易所代码:IRNT — Get Rating)和Oncology Pharma(OTCMKTS: ONPH — Get Rating)都是小型计算机和科技公司,但哪一项是更优的投资?我们将根据两家公司的收益、估值、股息、风险、机构所有权、分析师建议和盈利能力对两家公司进行比较。
Analyst Ratings
分析师评级
This is a summary of recent ratings and target prices for IronNet and Oncology Pharma, as reported by MarketBeat.
据MarketBeat报道,这是IronNet和Oncology Pharma的最新评级和目标价格的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
IronNet | 2 | 0 | 0 | 0 | 1.00 |
Oncology Pharma | 0 | 0 | 0 | 0 | N/A |
卖出评级 | 持有评级 | 买入评级 | 强劲的买入评级 | 评分分数 | |
ironNet | 2 | 0 | 0 | 0 | 1.00 |
肿瘤制药 | 0 | 0 | 0 | 0 | 不适用 |
IronNet presently has a consensus price target of $2.75, indicating a potential upside of 807.29%. Given IronNet's higher probable upside, analysts clearly believe IronNet is more favorable than Oncology Pharma.
IronNet目前的共识目标价为2.75美元,表明潜在的上涨空间为807.29%。鉴于IronNet可能的上行空间更高,分析师显然认为IronNet比Oncology Pharma更有利。
Institutional & Insider Ownership
机构和内部所有权
19.4% of IronNet shares are owned by institutional investors. Comparatively, 0.0% of Oncology Pharma shares are owned by institutional investors. 38.6% of IronNet shares are owned by company insiders. Comparatively, 18.0% of Oncology Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
19.4%的IronNet股票由机构投资者持有。相比之下,Oncology Pharma有0.0%的股份由机构投资者持有。38.6%的IronNet股票由公司内部人士持有。相比之下,18.0%的Oncology Pharma股份由公司内部人士持有。强大的机构所有权表明,大型基金经理、捐赠基金和对冲基金认为股票有望实现长期增长。
Earnings & Valuation
收益与估值
This table compares IronNet and Oncology Pharma's gross revenue, earnings per share and valuation.
该表比较了IronNet和Oncology Pharma的总收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
IronNet | $28.39 million | 1.11 | -$242.65 million | ($3.28) | -0.09 |
Oncology Pharma | N/A | N/A | N/A | N/A | N/A |
总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
ironNet | 2839 万美元 | 1.11 | -2.4265 亿美元 | (3.28 美元) | -0.09 |
肿瘤制药 | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
Oncology Pharma has lower revenue, but higher earnings than IronNet.
肿瘤药公司的收入较低,但收益高于IronNet。
Volatility & Risk
波动性与风险
IronNet has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Oncology Pharma has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500.
IronNet的beta值为1.3,这意味着其股价的波动性比标准普尔500指数高30%。相比之下,Oncology Pharma的beta值为0.05,这意味着其股价的波动性比标准普尔500指数低95%。
Profitability
盈利能力
This table compares IronNet and Oncology Pharma's net margins, return on equity and return on assets.
该表比较了IronNet和Oncology Pharma的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
IronNet | -1,052.76% | -458.41% | -161.81% |
Oncology Pharma | N/A | N/A | N/A |
净利润 | 股本回报率 | 资产回报率 | |
ironNet | -1,052.76% | -458.41% | -161.81% |
肿瘤制药 | 不适用 | 不适用 | 不适用 |
Summary
摘要
IronNet beats Oncology Pharma on 5 of the 8 factors compared between the two stocks.
与两只股票相比,IronNet在8个因素中的5个方面击败了Oncology Pharma。
About IronNet
关于 IronNet
(Get Rating)
(获取评级)
IronNet, Inc. designs and develops solutions for cyber-attacks. The company offers IronDefense, an advanced network detection and response solution that provides behavior-based and AI-driven analytics at the network level to detect anomalous activity at individual enterprises and prioritize the threats in its network; and IronDome, a threat-exchange solution that enables collective defense member enterprises to actively exchange individual anonymized cyber anomalies at machine speed in a community of public-private peers. It also provides a suite of technologies that provide real-time threat assessment and updates, behavioral modeling, big data analytics, and proactive threat detection and response capabilities; and consulting and training programs to protect against current and emerging cyber-threats. The company's services include cyber operations center, governance and maturity, cybersecurity readiness, incident response, and training services. It serves enterprise, defense, healthcare, government, and energy and utilities industries. The company was incorporated in 2014 and is headquartered in McLean, Virginia with additional offices in Raleigh, North Carolina; London, United Kingdom; and Singapore.
IronNet, Inc. 设计和开发网络攻击解决方案。该公司提供IronDefense,这是一种先进的网络检测和响应解决方案,可在网络层面提供基于行为和人工智能的分析,以检测个别企业的异常活动并对网络中的威胁进行优先排序;以及IronDome,一种威胁交换解决方案,使集体防御成员企业能够在公私同行社区中以机器速度主动交换个人匿名网络异常。它还提供了一套技术,可提供实时威胁评估和更新、行为建模、大数据分析以及主动威胁检测和响应能力;以及防范当前和新出现的网络威胁的咨询和培训计划。该公司的服务包括网络运营中心、治理和成熟度、网络安全准备、事件响应和培训服务。它为企业、国防、医疗保健、政府以及能源和公用事业行业提供服务。该公司成立于 2014 年,总部位于弗吉尼亚州麦克莱恩,并在北卡罗来纳州罗利、英国伦敦和新加坡设有办事处。
About Oncology Pharma
关于肿瘤制药
(Get Rating)
(获取评级)
Oncology Pharma, Inc. engages in the development, manufacture and commercialization of therapeutics. The company was founded by Marcel van Heesewijk on March 26, 1993 and is headquartered in San Francisco, CA.
Oncology Pharma, Inc. 从事疗法的开发、制造和商业化。该公司由 Marcel van Heesewijk 于 1993 年 3 月 26 日创立,总部位于加利福尼亚州旧金山。
Receive News & Ratings for IronNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IronNet and related companies with MarketBeat.com's FREE daily email newsletter.
接收 IronNet Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收IronNet及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。